MiR-340 Is a Biomarker for Selecting Treatment Between Chemotherapy and Allogeneic Transplantation in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) requires refined risk stratification tools to drive decisions concerning effective therapeutic strategies. Here, genome-wide screening was carried out for identifying miRNA molecules capable of predicting treatment outcome in AML patients based on the TCGA dataset. We id...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Mingshan Niu, Ninghan Zhang, Rong Wang, Tingting Shao, Yuan Feng, Yangling Shen, Xuejiao Liu, Kai Zhao, Shengyun Zhu, Linyan Xu, Yao Yao, Kailin Xu
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2019-10-01
Serija:	Frontiers in Oncology
Teme:	miR-340 acute myeloid leukemia clinical outcome chemotherapy allo-HCST
Online dostop:	https://www.frontiersin.org/article/10.3389/fonc.2019.01058/full
Oznake:	Označite Brez oznak, prvi označite!